| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/29/2009 | CN100482281C Method of treatment using anti-ErbB antibody-maytansinoid conjugates |
| 04/29/2009 | CN100482280C Highly compressible ethylcellulose for tableting |
| 04/29/2009 | CN100482277C Calicheamicin derivative-carrier conjugates |
| 04/29/2009 | CN100482276C Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 04/29/2009 | CN100482275C Solidified tissue immunological adjuvant |
| 04/29/2009 | CN100482266C Medical composite prepared by sarcandra and oldenlandia |
| 04/29/2009 | CN100482264C Shenling Chinese medicine preparation for strengthening body resistance |
| 04/29/2009 | CN100482240C Compound preparation of Chinese traditional medicine for anticancer |
| 04/29/2009 | CN100482233C Compositions and methods for treating amyloidosis |
| 04/29/2009 | CN100482224C Composite medicine for treating tumor and its application |
| 04/29/2009 | CN100482219C Novel compounds, pharmaceutical compositions containing same, and methods of use for same |
| 04/29/2009 | CN100482216C Use of hydroxide-releasing agents as skin permeation enhancers |
| 04/29/2009 | CN100482213C Monascus pellet and its preparing method |
| 04/29/2009 | CN100482211C Medicinal targeted local lipolysis |
| 04/28/2009 | US7524981 Phospholipid derivatives and process for the production there |
| 04/28/2009 | US7524969 Cardiovascular disorders; anticancer agents; antidiabetic agents; dietetics |
| 04/28/2009 | US7524956 Hemisynthetic method and new compounds |
| 04/28/2009 | US7524936 labeled monoclonal or polyclonal antibodies that preferentially binds oxidoreductase enzyme polypeptides, proteins, fragments, domain peptides or amino acid sequences having replacements, capable of superoxide production |
| 04/28/2009 | US7524932 Lactalbumin production process |
| 04/28/2009 | US7524930 polypeptides consisting of amino acid sequences or peptide fragments and drug carriers, used for inducing and/or activating human leukocyte antigens (HLA-A2)-restricted tumor-specific cytotoxic T lymphocytes; anticancer vaccines |
| 04/28/2009 | US7524883 Eponemycin and epoxomicin analogs and uses thereof |
| 04/28/2009 | US7524861 Process for the preparation of a hydrate of an anthranilic acid derivative |
| 04/28/2009 | US7524858 Substituted pyrroline kinase inhibitors |
| 04/28/2009 | US7524857 Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents |
| 04/28/2009 | US7524852 Bicyclic pyrimidine derivatives |
| 04/28/2009 | US7524850 1-{1-[4-(6-hydroxy-5-isobutyl-3-phenylpyrazin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; serine/threonine protein kinase; antiproliferative |
| 04/28/2009 | US7524849 5-arylpyrimidines as anticancer agents |
| 04/28/2009 | US7524847 Inhibit Dipeptidyl peptidase-IV; 7-(2-Butynyl)-3-methyl-3,7-dihydropurine-2,6-dione; suppress degradation of Glucagon-Like Peptide-1; enhance action of incretin; facilitate insulin secretion from pancreatic beta -cells due to glucose stimulus; postchallenge hyperglycemia, improved oral glucose tolerance |
| 04/28/2009 | US7524840 Inhibit angiogenesis, kinase activity; cancer tumors; convert a benzodiazepine lactam to an O-methyl ether; react ether with dimethyl acetal of N,N-dimethyl acetamide; react with hydrazine; 5-(2-chlorophenyl)-1,2-dihydro-7-fluoro-8-(3-(4-morpholinyl)propoxy))-3-methyl-pyrazolo[3,4-b][1,4]benzodiazepine |
| 04/28/2009 | US7524828 Immunostimulatory nucleic acid molecules |
| 04/28/2009 | US7524649 Chimeric polypeptide having a modified binding domain of growth hormone linked to a receptor binding domain of growth hormone receptor; treating giantism; acromegaly; cancer diabetic retinopathy; diabetic nephropathy, diabetic complications and any disease of growth hormone excess |
| 04/28/2009 | US7524643 Nucleotide sequences coding voltage gated calcium channels (VGCC) for treating neurological and cardiovascular disorders; anticonvulsant |
| 04/28/2009 | US7524502 Modified anti-TNF alpha antibody |
| 04/28/2009 | US7524488 Interleukin-18 mutants |
| 04/28/2009 | CA2510853C Pyrrolopyrimidine derivatives |
| 04/28/2009 | CA2429793C Interferon therapeutic effect enhancer |
| 04/28/2009 | CA2375259C Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| 04/28/2009 | CA2346396C 4,5-dihydro-isoxazole derivatives and their pharmaceutical use |
| 04/28/2009 | CA2334761C Composition comprising .beta.-hydroxy-.beta.-methylbutyric acid and at least one amino acid and methods of use |
| 04/28/2009 | CA2220195C Therapeutic oligonucleotides targeting the human mdr1 and mrp genes |
| 04/23/2009 | WO2009052394A2 Stem cell targeting of cancer, methods and compositions therefor |
| 04/23/2009 | WO2009052379A2 Improved antitumoral treatments |
| 04/23/2009 | WO2009052310A1 A3 adenosine receptor antagonists |
| 04/23/2009 | WO2009052288A1 Spiro-condensed 1, 3, 4-thiadiazole derivatives for inhibiting ksp kinesin activity |
| 04/23/2009 | WO2009052287A1 2 ' -flu0r0-2 ' -deoxytetrahydrouridines as cytidine deaminase inhibitors |
| 04/23/2009 | WO2009052264A2 Maleate salts of (e)-n-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| 04/23/2009 | WO2009052237A1 Inhibitors of c-fms kinase |
| 04/23/2009 | WO2009052231A1 Crystalline chemotherapeutic |
| 04/23/2009 | WO2009052230A1 Crystalline chemotherapeutic |
| 04/23/2009 | WO2009052229A1 Crystalline chemotherapeutic |
| 04/23/2009 | WO2009052226A1 Crystalline indazole-derived chemotherepeutic |
| 04/23/2009 | WO2009052225A1 Crystalline chemotherapeutic |
| 04/23/2009 | WO2009052145A1 Thienopyrimidine and pyrazolopyrimidine compounds and their use as mtor kinase and pi3 kinase inhibitors |
| 04/23/2009 | WO2009052090A2 Silicate containing compositions and methods of treatment |
| 04/23/2009 | WO2009052081A2 Antibodies that bind il-4 and/or il-13 and their uses |
| 04/23/2009 | WO2009051752A1 Novel lapachone compounds and methods of use thereof |
| 04/23/2009 | WO2009051739A1 Methods for protecting the skin from radiation insults |
| 04/23/2009 | WO2009051712A1 Dnai amphoteric liposome formulation |
| 04/23/2009 | WO2009051659A2 Therapeutic sirna molecules for reducing vegfr1 expression in vitro and in vivo |
| 04/23/2009 | WO2009051555A2 Modified mhc class i binding peptides |
| 04/23/2009 | WO2009051238A1 Mouse having human leukemic stem cell and leukemic non-stem cell amplified therein, and method for production thereof |
| 04/23/2009 | WO2009051201A1 Anti-bst2 antibody |
| 04/23/2009 | WO2009051078A1 Therapeutic gene expression system |
| 04/23/2009 | WO2009050898A1 Therapeutic agent for colorectal cancer |
| 04/23/2009 | WO2009050506A2 Combination 059 |
| 04/23/2009 | WO2009050486A2 F0xp3 : nfat inhibitor peptides for the treatment of cancer |
| 04/23/2009 | WO2009050321A1 Laforin-based cancer diagnosis and treatment method, biological elements for implementing same and use thereof |
| 04/23/2009 | WO2009050296A1 Improved antitumoral treatments |
| 04/23/2009 | WO2009050267A2 Il24 for inducing hyperproliferative or autoimmune cell death |
| 04/23/2009 | WO2009050143A1 Combinations of (1r, 2r, 3s, 4s) -n4- (3-aminocarbonylbicyclo [2. 2. 1] hept-5-ene-2-yl) - 5-fluoro-n2- [ ( 3 - methyl-4- (4 -methylpiperazin-1-yl] phenyl-2, 4-pyrimidineamine |
| 04/23/2009 | WO2009049961A2 New no-donor aspirin derivatives |
| 04/23/2009 | WO2009049841A1 Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
| 04/23/2009 | WO2009049743A1 5-cyano-thienopyridines for the treatment of tumors |
| 04/23/2009 | WO2009049525A1 Oxazinocamptothecin derivatives and their preparation and use |
| 04/23/2009 | WO2009049492A1 N-substituted aromatic hydrocarbon aniline and multi-substituted diarylether compounds, the preparation and the use of antitumor thereof |
| 04/23/2009 | WO2009049439A1 Preparative method of dihydrocucurbitacin f-25-o-acetate and the use thereof in the manufacture of medicaments for treating cancers |
| 04/23/2009 | WO2009049410A1 Clioquinol for the treatment of hematological malignancies |
| 04/23/2009 | WO2009049378A1 Lactone derivatives |
| 04/23/2009 | WO2009049370A1 Novel sulfated oligosaccharide derivatives |
| 04/23/2009 | WO2009030890A9 Pyrimidine compounds for the treatment of cancer, septic shock and/or primary open angle glaucoma |
| 04/23/2009 | WO2009027736A3 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer |
| 04/23/2009 | WO2009024667A3 Antitumour combinations containing a vegf inhibiting agent and irinotecan |
| 04/23/2009 | WO2009017822A3 Pi3 kinase modulators and methods of use |
| 04/23/2009 | WO2009007751A3 Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
| 04/23/2009 | WO2009007748A3 Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
| 04/23/2009 | WO2009004171A3 1-benzylpyrazole derivatives, preparation thereof and therapeutic use thereof |
| 04/23/2009 | WO2008152014A3 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases |
| 04/23/2009 | WO2008141107A3 Compositions that include a hydrophobic compound and a polyamino acid conjugate |
| 04/23/2009 | WO2008138658A3 Pharmaceutical compounds comprising abasic oligonucleotides |
| 04/23/2009 | WO2008101195A3 Drug resistance reversal in neoplastic disease |
| 04/23/2009 | US20090105478 Novel compounds |
| 04/23/2009 | US20090105454 Prophylactic/therapeutic agent for cancer |
| 04/23/2009 | US20090105341 Process for the production of trans-10, cis 12 octadecadienoic acid |
| 04/23/2009 | US20090105329 Methods of Treating Cancers with SAHA, Carboplatin, and Paclitaxel and Other Combination Therapies |
| 04/23/2009 | US20090105327 Dibenzocycloheptane compounds and pharmaceuticals containing these compounds |
| 04/23/2009 | US20090105326 Crystalline Chemotherapeutic |
| 04/23/2009 | US20090105324 Imidazole derivatives for use as edg-1 antagonists |
| 04/23/2009 | US20090105319 Naphthalene-based inhibitors of anti-apoptotic proteins |
| 04/23/2009 | US20090105306 Novel compounds as cannabinoid receptor ligands |
| 04/23/2009 | US20090105305 Therapeutic Agents - 550 |